StemTek is a global biopharmaceutical company with a clear stem cell focused research services portfolio in drug development for cancer treatment. Our interest is not just be the first line research services provider for the pharmaceutical industry but to go beyond current barriers in drug screening to overcome unmet needs for cancer treatment for the benefit of society as a whole.
Recent discoveries in cancer research and stem cells are allowing unprecedented breakthroughs in anti-cancer treatment approaches, creating new business opportunities in drug discovery.
StemTek uses state of the art technology and world class science to contribute to a novel generation of anti-cancer drugs. StemTek is dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy.
Drug screening against cancer stem cells based on 3D cell culture systems, such as tumor spheroid characterization, allows stronger, more efficient an reliable drug screening than conventional 2D based monolayer culture systems currently used by pharmaceutical industry.
StemTek has developed a portfolio added-value research services that allows customers to profile their pipeline of compounds for their effect on cancer stem cell populations, using 3D culture models (tumor spheroids) besides a variety of gold-standard approaches for cancer stem cell identification, benefiting from the extense experience of the scientific team at StemTek in cancer stem cell research.
After years of laboratory experience, Stemtek Therapeutics has developed an innovative solution, Cell2Sphere™, that enhances the biological relevance of your pre-clinical in vitro CSC 3D-based culture efficacy assays for novel cancer treatment discovery and validation.
The Cell2Sphere™ product kit includes three elements:
1.-A standard 96 well plastic plate that can be directly used in existing drug screening platforms.
2.-CSC enriched single cells in each well, the laboratory can add any compounds to be analyzed to the well.
3.-A proprietary culture medium.
Get a phenotypic readout of CSC function (spheroid formation), and viability assay in 3D using conventional laboratory equipment.
Standard 96 well plates allows for direct integration to existing drug screening platforms.
Plates are delivered frozen for long term storage and convenience, ideal for flexible experimental planning.
NO TRAINING NEEDED.
Anybody can perform 3D cell culture assays using the Cell2Sphere™ kit. Only minimal experience required in manipulating conventional tissue culture material.
Ad hoc cancer stem cell services:
Our experts can advise on appropriate models and plan and manage protocols in accordance with the aims of your study. Our ad-hoc department aims to provide customized solutions to suit our customers R&D needs. We can advise on all aspects of the process from basic cell work, to in vivo efficacy testing.
In vivo re-engraftment xenograft models:
Standard xenograft systems are treated with lead compound, then cells are extracted and inoculated to fresh animals comparing increasing number of cells to assess tumor initiation frequency. This is the gold standard assay for cancer stem cell function.
In vivo Non-cancer stem cell debulking Xenograft models:
Standard xenograft systems are treated with current standard of care chemotherapy, residual resistant tumors are enriched in cancer stem cells, that are then subsequently xenografted in fresh animals where the activity of the lead under study can be assessed.
In vivo tumor initiation xenograft models:
Pre-treated cell cultures are used to generate tumor xenograftIs in immunocompromised mice and tumor formation is measured upon time, compared to a vehicle pre-treated culture.
In vitro Cancer stem cell - Tumorospheres:
Cancer stem cells show the unique ability to grow as floating spheroids when seeded in suspension with defined culture media. Tumor spheroid 3D cell culture systems allow stronger, more efficient an reliable drug screening than conventional 2D based monolayer culture systems currently in use. From compound validation to 96 well based HTS. This assay is optimized for breast, colon, lung, prostate, pancreas and glioblastoma cell lines, although can we accommodate others. We conduct toxicity pre-screening to discard non-specific cytotoxics, aiming to uncover molecules specifically targeting cancer stem cells.
In vitro cancer stem cell phenotypic screening:
We are proficient in evaluating the effect of your drug candidates on the standard cancer stem cell markers and assays, such as surface marker expression or ALDH activity determination.
"In vitro Cancer stem cell Migration assay:"
Cancer stem cells are responsible for initiating new tumor lesions in distal location, that eventually may lead to a metastasis. Therefore it is critical to monitor the ability of cancer stem cells to migrate as a measure of invasive capacity thus a surrogate marker for metastasic potential. StemTek can measure the ability of spheroid derived cells to migrate on extracellular matrix covered plates and observing the speed of 2D growth as a measure of invasive potential of these cells.
**Cancer stem cell Gene expression:"
Characterization of stem cell related gene signatures, where we measure a panel of genes related to identification, homeostasis, growth and differentiation of stem cells. Allows the evaluation of potential leads in self-renewal and differentiation potential of stem cells, critical parameters for cancer progression.
Activation of masters regulators of pluripotency is associated with dynamic acquisition of stem cells traits that results in cancer stem cell behavior. We monitor these dynamics through stem cell related gene promoter activation using reporter assays in stable cellular models.
Ex vivo Human natural tumor screening:
Scientists at StemTek have worked with fresh human tumor material for many years, allowing cancer stem cell isolation for drug testing or treatment evaluation directly in patient material in vitro to help select between several treatment options.
StemTek collaborates with local hospitals in several research areas, facilitating acquisition of human material when possible, under strict ethical* regulatory conditions.
*The laws of Spain dictate that human material must be obtained after appropriate ethical approval has been granted for the specific purpose of a scientifically approved research project
StemTek Therapeutics has not received any reviews.
StemTek Therapeutics has not received any endorsements.